The adjuvant effect of interleukin-12 in a vaccine against Leishmania major - PubMed (original) (raw)

. 1994 Jan 14;263(5144):235-7.

doi: 10.1126/science.7904381.

Affiliations

• PMID: 7904381
• DOI: 10.1126/science.7904381

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major

L C Afonso et al. Science. 1994.

Abstract

Protection induced by vaccination depends on the capacity of the vaccine to elicit an appropriate immune response. In leishmaniasis, protection requires leishmanial-specific CD4+ T helper (TH) cells. Vaccination of BALB/c mice with leishmanial antigens and interleukin-12 (IL-12) promoted the development of leishmanial-specific CD4+ TH1 cells. These mice were resistant to subsequent infection with Leishmania major. Thus, IL-12 is an effective adjuvant for the initiation of protective cell-mediated immunity against leishmaniasis and may be an important component in other vaccines that need to induce cell-mediated immunity.

PubMed Disclaimer

Similar articles

• A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
  Yamakami K, Akao S, Sato M, Nitta Y, Miyazaki J, Tadakuma T. Yamakami K, et al. Parasitol Int. 2001 Jul;50(2):81-91. doi: 10.1016/s1383-5769(01)00070-8. Parasitol Int. 2001. PMID: 11438430
• LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
  Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, Ovendale PJ, Picha KS, Morrissey PJ, Grabstein KH, Campos-Neto A, Reed SG. Skeiky YA, et al. J Immunol. 1998 Dec 1;161(11):6171-9. J Immunol. 1998. PMID: 9834103
• What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
  Campos-Neto A. Campos-Neto A. Braz J Med Biol Res. 2005 Jul;38(7):979-84. doi: 10.1590/s0100-879x2005000700001. Epub 2005 Jul 4. Braz J Med Biol Res. 2005. PMID: 16007269 Review.
• The immunology of susceptibility and resistance to Leishmania major in mice.
  Sacks D, Noben-Trauth N. Sacks D, et al. Nat Rev Immunol. 2002 Nov;2(11):845-58. doi: 10.1038/nri933. Nat Rev Immunol. 2002. PMID: 12415308 Review.

Cited by

• New Approaches to the Prevention of Visceral Leishmaniasis: A Review of Recent Patents of Potential Candidates for a Chimeric Protein Vaccine.
  Oliveira DS, Zaldívar MF, Gonçalves AAM, Resende LA, Mariano RMDS, Pereira DFS, Conrado IDSS, Costa MAF, Lair DF, Vilas-Boas DF, Nakasone EN, Ameno IS, Goes WM, Silveira-Lemos D, Galdino AS, Nagem RAP, Dutra WO, Giunchetti RC. Oliveira DS, et al. Vaccines (Basel). 2024 Mar 5;12(3):271. doi: 10.3390/vaccines12030271. Vaccines (Basel). 2024. PMID: 38543905 Free PMC article. Review.
• Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory.
  Alvero AB, Fox A, Madina BR, Krady MM, Gogoi R, Chehade H, Nakaar V, Almassian B, Yarovinsky TO, Rutherford T, Mor G. Alvero AB, et al. Cancer Immunol Res. 2024 Feb 2;12(2):261-274. doi: 10.1158/2326-6066.CIR-23-0127. Cancer Immunol Res. 2024. PMID: 38078853 Free PMC article.
• Leishmania genetic exchange is mediated by IgM natural antibodies.
  Serafim TD, Iniguez E, Barletta ABF, Cecilio P, Doehl JSP, Short M, Lack J, Nair V, Disotuar M, Wilson T, Coutinho-Abreu IV, Meneses C, Andersen J, Alves E Silva TL, Oliveira F, Vega-Rodriguez J, Barillas-Mury C, Ribeiro JMC, Beverley SM, Kamhawi S, Valenzuela JG. Serafim TD, et al. Nature. 2023 Nov;623(7985):149-156. doi: 10.1038/s41586-023-06655-8. Epub 2023 Oct 25. Nature. 2023. PMID: 37880367
• In silico designing of a novel polyvalent multi-subunit peptide vaccine leveraging cross-immunity against human visceral and cutaneous leishmaniasis: an immunoinformatics-based approach.
  Bhattacharjee M, Banerjee M, Mukherjee A. Bhattacharjee M, et al. J Mol Model. 2023 Mar 16;29(4):99. doi: 10.1007/s00894-023-05503-w. J Mol Model. 2023. PMID: 36928431 Free PMC article.
• Chitosan particle stabilized Pickering emulsion/interleukin-12 adjuvant system for Pgp3 subunit vaccine elicits immune protection against genital chlamydial infection in mice.
  Shu M, Zhao L, Shi K, Lei W, Yang Y, Li Z. Shu M, et al. Front Immunol. 2022 Nov 23;13:989620. doi: 10.3389/fimmu.2022.989620. eCollection 2022. Front Immunol. 2022. PMID: 36505424 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program